

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jacqueline C. TIMANS

Application No.: Unknown

Filed: Herewith

For: MAMMALIAN CYTOKINES;  
RELATED REAGENTS AND  
METHODS

Examiner: Unknown

Art Unit: Unknown

"Express Mailing" mailing label number EL 982 850 978 US

Date of Deposit: October 27, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

by:



MELANIE LYONS

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

The materials as listed in the attached Form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB/08 listing references AA-BY.

All references listed on the attached Form PTO/SB/08 have been previously cited either by Applicant or the Examiner in the parent application, U.S. Patent Application NO. 09/398,412, filing date September 17, 1999, and copies of these references, and of a PCT Search Report dated April 27, 2000, should be available there. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached Form PTO/SB/08A. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: October 27, 2003

By: Tom Brody  
Tom Brody  
Agent for Applicants  
Reg. No. 46,433

***Customer No. 28008***

DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<p><b>Complete if Known</b></p>	
				Application Number	Unknown
				Filing Date	Herewith
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	5	Attorney Docket Number	DX0904KB

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AA	WO 99/06426	02-11-1999	PCT	pages 1 and 13	
	AB	WO 99/07850	02-18-1999	PCT		
	AC	WO 99/36541	07-22-1999	PCT		
	AD	EP 0 541 920 A1	05-19-1993	EPO		
	AE	EP 0 855 404 A1	07-29-1998	EPO		

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				<b>C mplete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	Unknown
<i>(Use as many sheets as necessary)</i>				Filing Date	Herewith
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	DX0904KB

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AF	P.E. AURON, et al., GenPept, Accession Number 124303, July 15, 1998. Definition: INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA) (CATABOLIN)"	
	AG	GREGORY J. BANCROFT, et al., Immunol. Reviews, 124:5-24, 1991. "Natural Immunity: A T-Cell-Independent Pathway of Macrophage Activation, Defined in the scid Mouse"	
	AH	J. FERNANDO BAZAN, et al., Nature, 379:591, February 15, 1996. "A newly defined interleukin-1?"	
	AI	MARCIA P. BELVIN, et al., Annu. Rev. Cell Dev. Biol., 12:393-416, 1996. "A conserved signaling pathway; The Drosophila TollDorsal Pathway"	
	AJ	M.J. CARRIER, GenBank, Accession Number X64532, June 25, 1997. Definition: "H.sapiens gene for interleukin-1 receptor antagonist"	
	AK	D.B. CARTER, et al., GenPept, Accession Number 124312, July 15, 1998. Definition: Interleukin-1 receptor antagonist protein precursor (IL-1RA) (ICIL-1RA) (IRAP)"	
	AL	FABIO COMINELLI, et al., J. Biol. Chem., 296(9):6962-6971, March 4, 1994. "Rabbit Interleukin-1 Receptor Antagonist"	
	AM	F. COMINELLI, et al., GenBank, Accession Number S68977, September 22, 1994. Definition: "sIL-1ra=interleukin-1 receptor antagonist secreted form [rabbits, colon tissue, mRNA, 574 nt.]"	
	AN	CHARLES A. DINARELLO, Blood, 77(8):1627-1652, April 15, 1991. "Interleukin-1 and Interleukin-Antagonism"	
	AO	CHARLES A. DINARELLO, The FASEB Journal, 8:1314-1325, December 1994. "The interleukin-1 family: 10 years of discovery"	
	AP	CHARLES A. DINARELLO, Blood, 87(6):2095-2147, March 15, 1996. "Biologic Basis for interleukin-1 in Disease"	
	AQ	W.H. GILMORE, et al., GenBank, Accession Number Z70047, March 11, 1996. Definition: "C.familiaris mRNA for interleukin-1 beta"	
	AR	F. GOTO, et al., GenBank, Accession Number D21832, April 21, 1994. Definition: "Rabbit mRNA for interleukin-1 receptor antagonist, complete cds."	
	AS	ANGELA M. GRONENBORN and G. MARIUS CLORE, Protein Engineering, 4(3):263-269, 1991. "Modeling the three-dimensional structure of the monocyte chemo-attractant and activating protein MCAF/MCP-1 on the basis of the solution structure of interleukin-8"	
	AT	H. HAMADA and R.C. MULLIGAN, et al., GenBank, Accession Number M57526, January 30, 1992. Definition: "Rabbit interleukin-1 receptor antagonist (IL1RA) mRNA, complete cds."	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	Unknown
<i>(Use as many sheets as necessary)</i>				Filing Date	Herewith
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	
<b>NON PATENT LITERATURE DOCUMENTS</b>					

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AU	STEVEN K. HANKS, et al., Methods in Enzymology, 200:38-62, 1991. "[2] Protein Kinase Catalytic Domain Sequence Database: Identification of Conserved Features of Primary Structure and Classification of Family Members"	
	AV	C.H. HANNON, et al., GenBank, Accession Number I09591, November 14, 1994. Definition: "Sequence 1 from Patent WO 8911540"	
	AW	C.H. HANNON, et al., GenBank, Accession Number I09592, November 14, 1994. Definition: "Sequence 3 from Patent WO 8911540"	
	AX	DAN HULTMARK, Nature, 367:116-117, January 13, 1994. "Ancient Relationships"	
	AY	C.A. HUNTER, et al., J. Immunology, 155:4347-4345, 1995. "IL-1 $\beta$ Is Required for IL-12 to induce Production of IFN- $\gamma$ by NK Cells. A Role for IL-1 $\beta$ in the T Cell-Independent Mechanism of Resistance Against Intracellular Pathogens."	
	AZ	J.K. JENKINS, et al., GenBank, Accession Number U65590, December 22, 1997. Definition: "Homo sapiens IL-1 receptor antagonist IL-1Ra (IL-1RN) gene, alternatively spliced forms, complete cds."	
	BA	BRUNO LEMAITRE, et al., Cell, 86:973-983, September 20, 1996. "The Dorsoventral Regulatory Gene Cassette spätsle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults"	
	BB	S.R. LEONG, GenBank, Accession Number X12497, March 13, 1995. Definition: "Bovine mRNA for interleukin-1 alpha"	
	BC	PATRICIA J. LODI, et al., Science, 263:1762-1767, March 25, 1994. "High-Resolution Structure of the $\beta$ Chemokine hMIP-1 $\beta$ by Multidimensional NMR"	
	BD	C.R. MALISZEWSKI, GenBank, Accession Number X52731, March 31, 1995. Definition: "Pig mRNA for interleukin 1-alpha"	
	BE	C.J. MARCH, et al., GenPept, Accession Number 124297, October 1, 1996. Definition: "Interleukin-1 alpha precursor (IL-1 alpha (hematopoietin-1))"	
	BF	M. MARRA, et al., GenBank, Accession Number AA030324, January 21, 1997. Definition: "mi08c10.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus musculus cDNA clone 459858 5', mRNA sequence"	
	BG	M. MARRA, et al., GenBank, Accession Number W08205, September 5, 1996. Definition: "mb49b11.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 332733 5' similar to PIR:A49031 A49031 interleukin 1 receptor antagonist - mouse ; mRNA sequence"	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	Unknown
<i>(Use as many sheets as necessary)</i>				Filing Date	Herewith
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	DX0904KB

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>BH</b>	Y. MASAAKI, et al., GenBank, Accession Number E01109, November 26, 1996. Definition: "cDNA sequence of human IL-1"	
	<b>BI</b>	Y. MASAAKI, et al., GenBank, Accession Number E01442, November 26, 1996. Definition: "cDNA encoding human IL-1"	
	<b>BJ</b>	CATHERINE J. MCMAHAN, et al., The EMBO Journal, 10(10):2821-2832, October 1991. "A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types"	
	<b>BK</b>	DONALD MORISATO & KATHRYN V. ANDERSON, Annu. Rev. Genetics, 29:371-399, 1995. "Signaling pathways that establish the dorsal-ventral pattern of the Drosophila embryo"	
	<b>BL</b>	T. NISHIDA, et al., GenBank, Accession Number D00403, January 19, 1992. Definition: "Rat interleukin-1 alpha mRNA, complete cds."	
	<b>BM</b>	HARUKI OKAMURA, et al., Nature, 378:88-91, November 2, 1995. "Cloning of a new cytokine that induces IFN-g production by T cells"	
	<b>BN</b>	JOOST J. OPPENHEIM, et al., Ann. Rev. Immunol. 9:617-648, 1991. "Properties of the novel proinflammatory supergene 'intercrine' cytokine family"	
	<b>BO</b>	LAURA L. PARKER, et al., NATURE, 363:736-738, June 24, 1993. "Phosphorylation and inactivation of the mitotic inhibitor Wee1 by the nim1/cdr1 kinase"	
	<b>BP</b>	HELGE ROTHE, et al., The Journal of Clinical Investigation, 99(3):469-474, February 1997. "Active Stage of Autoimmune Diabetes Is Associated with the Expression of a Novel Cytokine, IGIF, Which Is Located Near Idd2 "	
	<b>BQ</b>	ROGER A. SAYLE & E. JAMES MILNER-WHITE, TIBS, 20:374-376, September 1995. "RASMOL: biomolecular graphics for all"	
	<b>BR</b>	H.F. SEOW, GenBank, Accession Number X56972, May 26, 1992. Definition: "Ovine IL-1 beta mRNA for interleukin-1 beta"	
	<b>BS</b>	DIRK E. SMITH, et al. J. Biol. Chem. 275(2):1169-1175, Jan. 14, 2000. "Four new members expand the interleukin-1 superfamily"	
	<b>BT</b>	ROBERT STRAUSBERG (NCI-CGAP), GenBank, Accession No. AI014548, August 27, 1998. Definition: "ou40f01.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1628761 3', mRNA sequence."	
	<b>BU</b>	J.L. TELFORD, et al., GenBank, Accession Number X04964, September 16, 1994. Definition: "Murine interleukin-1 beta gene"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<p><b>C omplete if Known</b></p>	
				Application Number	Unknown
				Filing Date	Herewith
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	DX0904KB

## NON-PATENT LITERATURE DOCUMENTS

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.**

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.